230 related articles for article (PubMed ID: 15737842)
21. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Shim V; Gauthier ML; Sudilovsky D; Mantei K; Chew KL; Moore DH; Cha I; Tlsty TD; Esserman LJ
Cancer Res; 2003 May; 63(10):2347-50. PubMed ID: 12750248
[TBL] [Abstract][Full Text] [Related]
22. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
23. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ).
Gupta SK; Douglas-Jones AG; Fenn N; Morgan JM; Mansel RE
Cancer; 1997 Nov; 80(9):1740-5. PubMed ID: 9351542
[TBL] [Abstract][Full Text] [Related]
24. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
25. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
26. Tenascin patterns of expression in duct carcinoma in situ of the breast.
Iskaros BE; Sison CP; Hajdu SI
Ann Clin Lab Sci; 2000 Jul; 30(3):266-71. PubMed ID: 10945566
[TBL] [Abstract][Full Text] [Related]
27. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
28. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
29. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Ranger GS; Jewell A; Thomas V; Mokbel K
J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
[TBL] [Abstract][Full Text] [Related]
30. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
31. Extensive apoptosis in ductal carcinoma in situ of the breast.
Bodis S; Siziopikou KP; Schnitt SJ; Harris JR; Fisher DE
Cancer; 1996 May; 77(9):1831-5. PubMed ID: 8646681
[TBL] [Abstract][Full Text] [Related]
32. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
33. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Nielsen BS; Rank F; Illemann M; Lund LR; Danø K
Int J Cancer; 2007 May; 120(10):2086-95. PubMed ID: 17290405
[TBL] [Abstract][Full Text] [Related]
34. [Correlation of expression of heparanase to angiogenesis and prognosis of breast cancer].
Liu ZZ; Zhang HW; Wei B; Cui SD
Ai Zheng; 2004 Nov; 23(11):1342-5. PubMed ID: 15522187
[TBL] [Abstract][Full Text] [Related]
35. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
36. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Leo C; Faber S; Hentschel B; Höckel M; Horn LC
Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
[TBL] [Abstract][Full Text] [Related]
37. Ultrastructure of the periductal area of comedo carcinoma in situ of the breast.
Tang P; Teichberg S; Roberts B; Hajdu SI
Ann Clin Lab Sci; 2001 Jul; 31(3):284-90. PubMed ID: 11508833
[TBL] [Abstract][Full Text] [Related]
38. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.
Buerger H; Otterbach F; Simon R; Poremba C; Diallo R; Decker T; Riethdorf L; Brinkschmidt C; Dockhorn-Dworniczak B; Boecker W
J Pathol; 1999 Mar; 187(4):396-402. PubMed ID: 10398097
[TBL] [Abstract][Full Text] [Related]
39. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
[TBL] [Abstract][Full Text] [Related]
40. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
